Sharecare’s EBITDA reaches inflection point, says BTIG

BTIG analyst David Larsen reiterated a Buy rating and $5 price target on Sharecare after the company reported “good” Q3 results, with EBITDA reaching an inflection point. The firm believes that newly appointed CEO Brent Layton will seek to capture more of the healthcare premium within Enterprise, which BTIG believes is the “right strategy.”